l General Information |
Product Name | Idelalisib |
General description | Idelalisib is Kinase Inhibitor, and Cytochrome P450 3A Inhibitor. |
Synonym | 5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one; CAL-101;GS-1101 |
Purity | ≥98%(HPLC) | CAS Number | 870281-82-6 |
Formula | C22H18FN7O | Molecular Weight | 415.432 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥20mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Idelalisib is an orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. |
Application | 1. Antineoplastic Agents 2. Enzyme Inhibitors |
l Packaging & Storage |
Packaging | 10mg; 50mg; 250mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
